Cogent Biosciences, Inc. COGT
31.16 USD +0.10 (+0.32%)
Nov 4, 2026, 2:09 PM EST
29.94 Day range 32.03
13.78 52-week range 43.73
- YTD
- -12.27%
- 1 year
- +120.52%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 55.82 +79.1% upside
Now 31.16
- Target (low)
- 45.00
- Target (mean)
- 55.82
- Target (high)
- 62.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 12
- 1 month ago 12
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.55027 | -0.64 – -0.45 | -0.50 | -10.1% | 0 | 0.0% | 8 |
| Next quarter | -0.57946 | -0.73 – -0.48 | -0.5628 | -3.0% | 5.99M | 0.0% | 8 |
| Current year | -2.22 | -2.54 – -1.92 | -2.11 | -4.9% | 5.99M | 0.0% | 9 |
| Next year | -1.20 | -1.80 – -0.45 | -2.22 | +46.0% | 283.70M | +4637.4% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 17, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 12, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 29, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 17, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 18, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Jan 21, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jan 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 19, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 8, 2025 | Needham | Reiterated | Hold | Hold |
| Nov 13, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 11, 2025 | Baird | Maintained | Neutral | Neutral |
| Nov 10, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Nov 4, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 21, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 16, 2025 | Stifel | Initiated | — | Hold |
| Sep 3, 2025 | Raymond James | Initiated | — | Strong Buy |
| Aug 25, 2025 | Guggenheim | Maintained | Buy | Buy |
| Aug 7, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 18, 2025 | Citigroup | Maintained | Buy | Buy |
| Jul 10, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 8, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Jul 8, 2025 | Baird | Maintained | Neutral | Neutral |
| Jul 7, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Jul 7, 2025 | Jefferies | Maintained | Buy | Buy |
| Jun 17, 2025 | Needham | Reiterated | Hold | Hold |